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Selected Topics on FK 506, With Special References to Rescue of 
Extrahepatic Whole Organ Grafts, Transplantation of "Forbidden 
Organs," Side Effects, Mechanisms, and Practical Pharmacokinetics 
T.E. Starzl, K. Abu-Elmagd, A. Tzakis, J.J. Fung, K.A. Porter, and S. Todo 
EXPERIMENT AL and clinical studies of FK 506 dur-ing the last 3 years have positioned this powerful 
drug in a very favorable light. Rather than summarizing 
these studies. we will comment on several issues that will 
not be covered in other presentations. 
RESCUE OF REJECTING WHOLE ORGAN GRAFTS 
FK 506 was first tested clinically and shown to be effective 
for rescuing failing liver grafts. ,·2 Armitage reported a 
follow-up about heart grafts that have been salvaged with 
this drug. 3 •4 
Kidney rescue attempts have been limited by the cumu-
lative toxicity of cyclosporine (Cy Al and FK 506 at the 
time of switch. 1.5 However. such trials are starting. The 
kidney recipient whose course is summarized in Table I 
had developed a posttransplant nephrotic syndrome and 
was excreting about 10 gld albumin 13 months after cadav-
eric transplantation. His serum creatinine and clearance 
still were adequate. After changing to FK 506 and stopping 
Cy A. azathioprine. and steroids. the proteinuria was dra-
matically reduced along with normalization of serum cho-
lesterol and albumin levels. The response was similar to 
that recently reported in nontransplant nephrotic patients.1> 
for example. the 30-month-old child depicted in Table 2. 
The child's albumin excretion was almost completely shut 
off within 2 weeks of therapy while depressed serum 
albumin and elevated serum cholesterol levels were re-
stored to normal. Here also. previous steroid treatment 
was stopped. 
TRANSPLANTATION OF FORBIDDEN ORGANS 
FK 506 will be used principally as primary therapy in 
transplantation; trials for livers. hearts. lungs. and kid-
neysl.l7.H are summarized separately. Using FK 506. it 
may be possible to perform procedures that until now have 
Table 1. Nephrosis in 49-Year-Old Cadaveric Kidney ReCipient 
(SWitch 13 Months Postoperative) 
evA 
Urinary protein Img 24') 9768 
Serum creatlmne Img all 15 
Serum cholesterol (mg dl) 289' 
Serum albumin (g dU 3.7 
Predmsone (mq a) 15 
Azathioprine Imq d) 150 
·Whtle on anllCflOIeslorolomlC aruQ 
1 mo 
1697 
17 
183 
38 
0 
0 
FK 506 
5 mo 
100 
16 
173 
4.5 
o 
o 
Table 2. Focal Sclerosing Glomerulonephritis 
Before 
FKS06 3mo 6mo 
Urinary protein (mg/24°) 1406 63 0 
Serum creatinine (mg/dl) 0.3 0.1 0.3 
Creatinine clearance (mUminl 82.0 86.0 NO 
1.73 m2 ) 
Serum cholesterol (mg/dL) 630 169 146 
Serum albumin (g;dL) 1.7 3.7 3.9 
Prednisone (mg/d) 175-35 0 0 
Note: 30·month-old boy. 148 kg. 
been impractical or impossible. For example. intestinal 
and multi visceral allotransplantation in rats can be accom-
plished easily with rather small doses of FK 506 for only 2 
postoperative weeks. and with permanent survival.9 Clin-
ically. a patient who lost his small bowel and colon after a 
gunshot wound to the superior mesenteric artery received 
a complete small bowel transplant on May 2. 1990 (Fig I). 
He is now on an unrestricted oral diet and is being treated 
with 0.2 mglkg oral FK 506 and 10 mg prednisone/d. He 
has good intestinal absorption. and a normal mucosal 
pattern on his gastrointestinal (Gil series (Fig 2). Shown 
also in Fig 2 is his preoperative condition with only a 
stomach and a blind sac of duodenum. Two more patients 
have had successful complete intestinal grafts in continuity 
with liver grafts. Grant et alit) reported on hepaticoenteric 
grafts under (CyA) earlier this year. The prospect of 
transplanting a variety of hollow viscus organs is good. 
Pancreatic islet graft transplantation also has been suc-
cessfully pertormed under FK 506 in patients who are now 
insulin independent more than 6 months after upper ab-
dominal cluster resections (including total pancreatec-
tomyl and liver plus intraportal islet transplantation. These 
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Fig 1. Patient who received a complete small bowel transplant 
from a cadaveric donor on May 2. 1990. The ileostomy is seen in 
the right lower quadrant. The oval skin defect In the right upper 
quadrant was the site of a Jejunostomy that was brought out as a 
"chimney. and later closed when the patient was able to eat. 
are the first unambiguouslv Iuccl:I~ful i,let transplants in 
humans. I I 
AUTOIMMUNE DISEASES 
The impact of FK 5()() and pre\umanl\ (lther new genera-
tion immunosuppressants will go hevond transplantation. 
and rna\' reduce the numner (If \\hole organ candidates 
who \utkr from autoimmune dl~ca~esK FOllr autoimmunc 
di,eases ~drcady h~lve hcen tre~ltcd: hcmolytic uremIC 
wndrol1le lunc .:asci. I1c[lhrutl': ~y nliwille <IS mentloncd 
c:arlier Itile ,ase,!. [lsuri~lsis If,'m c~l~es!K and [l\'udcrma 
t:allgrefl(lsllill 111\(l Cdses'. \\'ith tile s"in dl,orders, the 
ra[lldit\ "I re'[lollsc ha~ beel1 m~lrtlclgiarlyD cas' t" dllCU-
ment !I:r~l[lhlcdhKD: Within ~ e'r; lid\' :lItl:r st<lrtlllg FK 
'Of), <111 elket ,:111 he SCCI1 and ~1f1er ~ tll" I\eeks, the ,kill 
lesions llf tilcs..: l"s~lrdcr" Ilcrc hcaled. rhc list (If call1h-
datI: :lll!llllTllllllnC dlseascs Is [e ll1l!, ~llld 111 manl fflItallce~ 
there ~fre anll11al ~fllal~llK!ue dlIed~CD tilat [lerrnil Cy~ld [lre-
clil1lCal tcstlll!!. h'r ey~ff1l[licK yll1r~lsc d .tI" 11:11": [lrll\ Ided 
Irllll1 IlB 1",lt C\[lCrIIllCllts 'th'lllC 'lI1'rllrI I,ll' Irlals 111 
ilhllillHicpClldcll1 "fabctKK:~ [l1l'llltU'. 
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Fig 2. GI series of same pallent as Fig 1. He IS a 31-year-old 
pallent who lost hiS small bowel and colon In early November 
1989. after a aunshOt wound to the superior mesenteric artery. (A) 
ReSidual GI Iract that conSisted of the stomach and the duodenal 
lOOp that ended bllnalv. (8) GI senes With a delayed film of a normal 
small bowel homoaraf1. The arrow III the left upper quadrant IS the 
'eSldual OUIPoucnlng trom a lelunal cnlmnev Ihat was brougnt to 
'he SKin ana cosea alter 2 ;Jostoperatlve monlnS [see Fig 1 i 
l 
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FK 506 CyA 
Nephrotoxicity +. ++ 
Neurotoxicity + + 
Diabetogenicity + + 
Growth Effects 
Hirsutism a +++ 
Gingival hyperplasia a ++ 
Facial brutalization a + 
Hepatotrophic ++++ +++ 
Gynecomastia a + 
Other metabolic effects (in blood) 
Cholesterol increase at ++ 
Uric acid increase +? ++ 
·MInor if any hypertension. . 
tHowever. in rats Van Thiel has shown an increase in cholesterol synlhasls and 
serum concentration (unpublished). 
TOXIC AND METABOLIC PROFILE 
The full extent of these applications in and out of trans-
plantation will depend on the toxicity profile of FK 506 
(Table 3). The metabolic effects of this drug are wide 
ranging. and resemble qualitatively those of Cy A. 14 How-
ever. much evidence gathered from animals and humans 
suggests that its therapeutic index is better. Both drugs are 
moderately diabetogenic by inhibiting the release of insulin 
from islets. and possibly by increasing peripheral insulin 
resistance. IS Both are neurotoxic. FK 506 causes little if 
any hypertension. Other questions of nephrotoxicity will 
be considered further on. Lipid and uric acid metabolism 
are not seriously perturbed with FK 506. We have not seen 
gingival hyperplasia. hirsutism. or coarsening of the facial 
features in FK 506-treated patients. These various quali-
ties are dose related. Such drug comparisons are flawed by 
the confounding factor of steroid need that appears to be 
less with FK 506. 
HEPATIC GROWTH CONTROL 
However. we are not discussing a competition between 
drugs. but rather an understanding of their uses and 
actions. A growth control effect of FK 506 is augmentation 
of the regeneration that occurs after partial hepatectomy. If> 
This normal regeneration response to 70% hepatectomy is 
also increased in rats treated with CyA,If>.19 
FK 506 is profoundly hepatotrophic in other ways as can 
be shown with a simple experiment with Eck fistula in 
which the drug is infused into one of the tied off portal 
veins above the completely diverting portacaval shunt (Fig 
3). Each experiment is its own control since the structure 
of the infused liver lobes can be compared with those not 
directly exposed to the drug. In the lobes directly exposed 
to FK 506 infusion (Fig 4) the hepatocytes are spared the 
atrophy, fat accumulation. and disruption and distortion of 
the organelles that occur on the unprotected (noninfusedl 
~ideI ~EF Such experiments have shown that FK 506 can 
prevent liver injury and promote liver healing. This may 
explain in part the remarkable effectiveness of this drug for 
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Fig 3. Experiment to test the hepatotrophic effect of FK 506, A 
completely diverting portacaval shunt is constructed, and the d~g 
being tested is infused over 4 days into the tied off left portal vein. 
The morphologic changes in the infused left lobes can be com-
pared with those in the right lobes (see Fig 4). 
liver transplantation. It is noteworthy that CyA is also 
hepatotrophic,21 
FK 506 AND CyA CONVERGENCE THROUGH PPlase 
Because FK 506 and CyA are unrelated. the similarity of 
their desired as well as other effects was puzzling. The 
mystery was partly lifted 9 months ago by Siekierka et al22 
and Harding et al23 who showed that FK 506 and CyA 
have different cytosolic binding sites but that these binding 
sites had in common a recently discovered enzyme called 
peptidyl-prolyl isomerase (PPlase) that facilitates protein 
folding,24 We have suggested that CyA. FK 506. and also 
a third drug. Rapamycin (which has recently surfaced) act 
in some way by PPlase inhibition. 14.2o If so. we could 
better understand. and eventually even predict. the wide 
range of physiologic effects of such drugs. Mark Lorber of 
Yale has shown that cyclophilin. the binding site of Cy A. 
is in the cytoplasm of essentially all mammalian tissues and 
even in the nuclei of some cells (unpublished observations. 
August 3, 1990). Lorber's work had. at least by implica-
tion. defined the extent of the PPlase network and made it 
clear why there were so many consequences of its use that 
were not limited to the immune system. Little imagination 
is required to associate the dense concentration of cyclo-
Table 4. Recovery After Liver Transplantation 
Class Bilirubin· 2 mg'dL ICU'Bound 
<lad <4 d 
II IO·20d >4d 
III up to 1.5 mo Chronic 
IV c·1 mo or never Chronic 
AbbreViation: ICU. IntenSIVe care unit. 
--
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Fig 4. Dog liver 4 days after Eck Fistula. and selective 
continuous infusion of FK 506 into the left portal vein. (A) 
Biopsy from a left lobe which had been directly infused with 
FK 506. (8) Biopsy noninfused infusion right lobe. The 
design of the experiment is shown in Fig 3. H&E x 120. 
philin in nervous, renaL and pancreatic tissues with neu-
rotoxicity. nephrotoxicity. and diabetogenicity. 
LIVER FUNCTION AND FK 506 METABOLISM 
The optimal use of FK 506 has not yet been standardized 
because questions remain concerning the influence of 
hepatic dysfunction on FK 506 dose requirements. plasma 
FK 506 levels. and toxicity in patients. We have examined 
these issues in 49 patients who underwent liver replace-
ment under FK 506 and low doses of prednisone. Although 
47 (96%) of these recipients have survived. they could be 
stratified (Table 4) according to the quality of initial graft 
function: class I patients being those with superior graft 
function. class 4 patients being those with catastrophic 
graft injury. and the other classes being in between. All of 
the class 3 and 4 patients had prolonged stays in the 
intensive care unit with ventilator dependence. a high rate 
of tracheostomy. and a protracted need for I V drug dosing. 
especially in the class 4 recipients. 
The plasma FK 506 trough levels postoperatively re-
Ilected the stratification. Patients with the best grafts had 
the lowest perioperative plasma trough levels while those 
917 
with severely dysfunctional grafts (class 4) had astronom-
ical rises in plasma FK 506 in spite of curtailment of doses 
(Fig 5). Patients with moderate (class 2) or severe (class 3) 
but reversible liver damage appeared to "auto regulate" 
the plasma trough levels which decreased at the same time 
as hepatic function returned and with little dose a<ljust-
ment (Fig 5). 
Renal function was severely impaired requiring dialysis 
in more than 25% of class 3 patients in almost all of the 
class 4 patients. This was obviously multifactorial includ-
ing sepsis. hypotension, and the use of nephrotoxic anti-
biotics. However. renal failure and high plasma blood 
levels in patients with hepatic dysfunction seemed to be 
associated (Fig 6). The renal injury was reversible. By the 
end of this 60-day study period. five patients were still on 
dialysis but three have subsequently recovered from renal 
failure leaving only two who are currently being weaned 
from dialysis. 
The take home message is clear. that downward dose 
adjustments guided by careful monitoring must be consid-
ered if there is abnormal liver function. Furthermore, liver 
20 1 _ Cia •• I (n=I.) ..... Cia •• til (":10' 
15 i --- CI ••• II (n: 17) ...... CI ... IV '":8' 
Fig 5. The eHect of liver gran 
function on FK 506 doses and 
plasma levels. Note that the low· 
est doses and highest plasma 
levels were In the patients with 
unsatISfactory earlv heoatlc func· 
tlon. 
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Fig 6. FK 506 plasma levels 
and renal failure in liver recipi-
ents. Some of class 3 and most 
of class 4 patients with early graft 
dysfunction and persistent high 
FK 506 plasma levels required 
postoperative dialysis for some 
lime. 5 10 15 20 25 30 35 
function tests should be part of the baseline information 
before starting FK 506 for any reason. 
OVERDOSAGE WITH IV FK 506 
Another practical warning from these studies was that 
dangerous IV dosing can occur. In the 49 patients. 0.075 
mglkg FK 506 were given IV over 4 hours every 12 hours. 
Even in the class I and 2 liver recipients. there was a 
transient increase in plasma FK 506 to potentially toxic 
levels and temporary renal dysfunction; the same thing 
was noted in heart recipients (Fig 7). These increases 
receded with conversion to oral doses of 0.15 mg/kg every 
12 hours. Because the oral absorption of FK 506 usually is 
only 20% to 30%. we believe that our IV dosing was 
systematically too high. The total daily quantity of IV FK 
506 probably should be one fourth to one third of the oral 
dose instead of the one half which we were using. 
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Fig 7. FK 506 doses, plasma levels. and kidney function in liver 
(classes 1 and 2) and heart transplant recipients. In both groups, 
IV administrations of FK 506 within the first 5 postoperative days 
were associated with the highest plasma levels and maximal 
increase in blood urea nitrogen. 
10 50 55 10 
It may be that continuous FK 506 infusion instead ofthe 
4-hour infusion method is preferable, but preliminary com-
parisons in these liver recipients (8 and 14 in the respective 
groups) have not shown a difference between the pulse vs 
continuous infusions either in the trough levels or the 
perioperative renal function (Fig 8). 
SUMMARY 
FK 506 is a superior immunosuppressive agent that should 
improve the grafting of organs that already are part of our 
every day transplant practices, as well as those which are 
presently impractical. Immune intervention for serious 
autoimmune diseases also should be a more attractive 
option with this drug. Lessons are still being learned about 
dosage and what determines safe dose schedules. At a 
basic level. the study of FK 506 and its comparison to Cy A 
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Fig 8. The effect of 4·hour (every 12 hours) and continuous IV 
infusion of FK 506 within the first 5 postoperative days on FK 506 
plasma levels and renal function in liver recipients with good 
hepatic function. 
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may have shed light on mechanisms and characteristics of 
the whole class of so-called macrolide immunosuppres-
sants and their cytosolic binding sites. 
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